Intranasal Vaccination Promotes Detrimental Th17-Mediated Immunity against Influenza Infection

English version České info

Influenza disease is a global health issue that causes significant morbidity and mortality through seasonal epidemics. Currently, inactivated influenza virus vaccines given intramuscularly or live attenuated influenza virus vaccines administered intranasally are the only approved options for vaccination against influenza virus in humans. We evaluated the efficacy of a synthetic toll-like receptor 4 agonist CRX-601 as an adjuvant for enhancing vaccine-induced protection against influenza infection. Intranasal administration of CRX-601 adjuvant combined with detergent split-influenza antigen (A/Uruguay/716/2007 (H3N2)) generated strong local and systemic immunity against co-administered influenza antigens while exhibiting high efficacy against two heterotypic influenza challenges. Intranasal vaccination with CRX-601 adjuvanted vaccines promoted antigen-specific IgG and IgA antibody responses and the generation of polyfunctional antigen-specific Th17 cells (CD4⁺IL-17A⁺TNFα⁺). Following challenge with influenza virus, vaccinated mice transiently exhibited increased weight loss and morbidity during early stages of disease but eventually controlled infection. This disease exacerbation following influenza infection in vaccinated mice was dependent on both the route of vaccination and the addition of the adjuvant. Neutralization of IL-17A confirmed a detrimental role for this cytokine during influenza infection. The expansion of vaccine-primed Th17 cells during influenza infection was also accompanied by an augmented lung neutrophilic response, which was partially responsible for mediating the increased morbidity. This discovery is of significance in the field of vaccinology, as it highlights the importance of both route of vaccination and adjuvant selection in vaccine development

Vyšlo v časopise: Intranasal Vaccination Promotes Detrimental Th17-Mediated Immunity against Influenza Infection. PLoS Pathog 10(1): e32767. doi:10.1371/journal.ppat.1003875
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003875

Souhrn

Zdroje

1. CoxRJ, BrokstadKA, OgraP (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1–15.

2. de JongJC, BeyerWE, PalacheAM, RimmelzwaanGF, OsterhausAD (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61: 94–99.

3. PavotV, RochereauN, GeninC, VerrierB, PaulS (2012) New insights in mucosal vaccine development. Vaccine 30: 142–154.

4. OsterholmMT, KelleyNS, SommerA, BelongiaEA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36–44.

5. BaldridgeJR, YorgensenY, WardJR, UlrichJT (2000) Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18: 2416–2425.

6. CluffCW, BaldridgeJR, StoverAG, EvansJT, JohnsonDA, et al. (2005) Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 73: 3044–3052.

7. StoverAG, da SilvaCJ, EvansJT, CluffCW, ElliottMW, et al. (2004) Structure-activity relationship of synthetic toll-like receptor 4 agonists. J Biol Chem 279: 4440–4449.

8. BowenWS, MinnsLA, JohnsonDA, MitchellTC, HuttonMM, et al. (2012) Selective TRIF-Dependent Signaling by a Synthetic Toll-Like Receptor 4 Agonist. Sci Signal 5: ra13.

9. BaldridgeJR, CluffCW, EvansJT, LacyMJ, StephensJR, et al. (2002) Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J Endotoxin Res 8: 453–458.

10. BazinHG, MurrayTJ, BowenWS, MozaffarianA, FlingSP, et al. (2008) The ‘Ethereal’ nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett 18: 5350–5354.

11. FriesLF, GordonDM, RichardsRL, EganJE, HollingdaleMR, et al. (1992) Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A 89: 358–362.

12. HeurtaultB, FrischB, PonsF (2010) Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv 7: 829–844.

13. CroweCR, ChenK, PociaskDA, AlcornJF, KrivichC, et al. (2009) Critical role of IL-17RA in immunopathology of influenza infection. J Immunol 183: 5301–5310.

14. EichelbergerM, AllanW, CardingSR, BottomlyK, DohertyPC (1991) Activation status of the CD4–8− gamma delta-T cells recovered from mice with influenza pneumonia. J Immunol 147: 2069–2074.

15. BettelliE, OukkaM, KuchrooVK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8: 345–350.

16. BazM, SamantM, ZekkiH, Tribout-JoverP, PlanteM, et al. (2012) Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 19: 209–218.

17. ZygmuntBM, RharbaouiF, GroebeL, GuzmanCA (2009) Intranasal immunization promotes th17 immune responses. J Immunol 183: 6933–6938.

18. HamadaH, Garcia-HernandezML, ReomeJB, MisraSK, StruttTM, et al. (2009) Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 182: 3469–3481.

19. McKinstryKK, StruttTM, BuckA, CurtisJD, DibbleJP, et al. (2009) IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 182: 7353–7363.

20. KudvaA, SchellerEV, RobinsonKM, CroweCR, ChoiSM, et al. (2011) Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 186: 1666–1674.

21. RutzS, EidenschenkC, OuyangW (2013) IL-22, not simply a Th17 cytokine. Immunol Rev 252: 116–132.

22. SonnenbergGF, NairMG, KirnTJ, ZaphC, FouserLA, et al. (2010) Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 207: 1293–1305.

23. KhaderSA, GuglaniL, Rangel-MorenoJ, GopalR, JuneckoBA, et al. (2011) IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 187: 5402–5407.

24. WillimanJ, LockhartE, SlobbeL, BuchanG, BairdM (2006) The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. Vaccine 24: 4471–4474.

25. WillimanJ, YoungS, BuchanG, SlobbeL, WilsonM, et al. (2008) DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza. Vaccine 26: 5153–5158.

26. BhanU, BallingerMN, ZengX, NewsteadMJ, CornicelliMD, et al. (2010) Cooperative interactions between TLR4 and TLR9 regulate interleukin 23 and 17 production in a murine model of gram negative bacterial pneumonia. PLoS One 5: e9896.

27. WangX, ChanCC, YangM, DengJ, PoonVK, et al. (2011) A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. Cell Mol Immunol 8: 462–468.

28. KhaderSA, BellGK, PearlJE, FountainJJ, Rangel-MorenoJ, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369–377.

29. FossiezF, BanchereauJ, MurrayR, VanKC, GarroneP, et al. (1998) Interleukin-17. Int Rev Immunol 16: 541–551.

30. BulekK, LiuC, SwaidaniS, WangL, PageRC, et al. (2011) The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 12: 844–852.

31. FujisawaH (2008) Neutrophils play an essential role in cooperation with antibody in both protection against and recovery from pulmonary infection with influenza virus in mice. J Virol 82: 2772–2783.

32. TateMD, BrooksAG, ReadingPC, MinternJD (2011) Neutrophils sustain effective CD8(+) T-cell responses in the respiratory tract following influenza infection. Immunol Cell Biol 90: 197–205.

33. RomanE, MillerE, HarmsenA, WileyJ, Von AndrianUH, et al. (2002) CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 196: 957–968.

34. WilkinsonTM, LiCK, ChuiCS, HuangAK, PerkinsM, et al. (2012) Preexisting influenza-specific CD4(+) T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274–280.